Expert Interview
A Second View: Comparing EyePoint's EYP-1901 and 4D Molecular Therapeutics' gene therapy, 4D-150 for the treatment of wet-AMD
Ticker(s): EYPT, FDMTInstitution: UC Davis
- Associate Professor of Medicine and retina specialist at UC Davis.
- Manages hundreds of patients with wet-AMD and 50 patients with Geographic atrophy; treats all forms of medical and surgical diseases of the retina.
- Research focus on retinal cell replacement and gene therapy approaches for photoreceptor diseases; special interest and focus in the diagnosis and management of inherited retinal diseases.
Please describe your clinical practice; how many patients with wet AMD do you currently treat on a yearly basis, what percent of your patients could benefit from upcoming treatments? How much need is there for a gene therapy like 4D-150?
Could you please explain to us the mechanism of action behind FDMT’s gene therapy, the intravitreal vector, R100, and the payload that expresses aflibercept and a VEGF-C RNAi via directed evolution (Therapeutic Vector Evolution platform)? What are the pros and cons of this approach, vs standard of care?
Added By: slingshot_insightsCould you please comment on the reported aflibercept expression data in the aqueous humor of the eye at 12 weeks after injection?
How important is the reported reduced annualized anti-VEGF injection rate (by 96.7%)?
What other applications could the company’s R100 intravitreal vector have? In what other indications do you see it benefiting patients?
What would you like to see in the future in regards to BCVA or OCT data, in order for this therapy to have better outcomes for your patients vs standard of care?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
